U.S. Markets close in 1 hr 44 mins
  • S&P 500

    4,396.51
    -22.64 (-0.51%)
     
  • Dow 30

    34,926.13
    -158.40 (-0.45%)
     
  • Nasdaq

    14,673.01
    -105.26 (-0.71%)
     
  • Russell 2000

    2,226.60
    -13.43 (-0.60%)
     
  • Crude Oil

    74.13
    +0.51 (+0.69%)
     
  • Gold

    1,816.50
    -19.30 (-1.05%)
     
  • Silver

    25.52
    -0.26 (-1.00%)
     
  • EUR/USD

    1.1864
    -0.0032 (-0.2729%)
     
  • 10-Yr Bond

    1.2320
    -0.0370 (-2.92%)
     
  • Vix

    18.02
    +0.32 (+1.81%)
     
  • GBP/USD

    1.3894
    -0.0063 (-0.4543%)
     
  • USD/JPY

    109.7900
    +0.3290 (+0.3006%)
     
  • BTC-USD

    39,036.07
    -635.35 (-1.60%)
     
  • CMC Crypto 200

    927.50
    -22.40 (-2.36%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

Abbott beats profit estimates as medical device sales rebound

·1 min read
Boxes of Abbott's heart stents are pictured inside a store at a hospital in New Delhi

(Reuters) -Abbott Laboratories beat quarterly profit estimates on Thursday, driven by a rebound in its non-COVID-19 testing business and sales of its medical devices as vaccinations encouraged Americans to resume non-urgent procedures.

The strong results saw the company join rival Quest Diagnostics in signaling a recovery in their mainstay businesses, after a year in which they had to depend on coronavirus testing to bring in sales.

Abbott said its second-quarter sales, excluding COVID testing, rose more than 11% on an organic basis from the pre-pandemic levels recorded in 2019.

Its worldwide diagnostics revenue, excluding coronavirus testing, increased 42.5% from a year earlier, while medical devices sales rose 51.3% on the back of growth in its heart devices business.

But the rise in vaccinations pulled down its COVID-19 testing-related sales to $1.3 billion, from $2.2 billion in the previous quarter.

The company reiterated its 2021 adjusted earnings forecast of $4.30 to $4.50 per share from continuing operations.

The robust quarterly performance is a positive sign for the continued recovery in the medical device industry, J.P.Morgan analyst Robbie Marcus said in a note.

Marcus added that the company's outlook "leaves room at both ends to continue to adjust to the evolving COVID landscape."

Excluding items, Abbott earned $1.17 per share, beating analysts' estimates of $1.02 per share, according to Refinitiv IBES data.

(Reporting by Amruta Khandekar and Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber and Aditya Soni)